CD19 and acute lymphoblastic leukemia: The success of these early researches and trials sets the basis for a larger clinical trial in a CD19-targeted CAR-T therapy called tisagenlecleucel (KymriahTM) for children and adolescents with acute lymphoblastic leukemia.